Allergy Deal Boosts Astellas's Pipeline, Allows Immunomic Refocus
This article was originally published in Scrip
Executive Summary
Astellas is making good on its strategic intention to expand in vaccines and immunology, paying $300m upfront for worldwide rights to Immunomic's technology and pipeline for DNA vaccines against human allergies, in a deal that will also allow the US biotech to focus on other applications including oncology.
You may also be interested in...
Astellas Builds Vaccine Portfolio With Affinivax Pneumococcal Candidate
Despite one recent setback, Astellas is continuing to expand its vaccines business through a new global deal for Affinivax's lead MAPS pneumococcal product, in a move that builds on earlier research links between the companies.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.